Imugene Ltd has released a press release.
Oncolytic Virotherapy CF33 Patent Granted in Japan
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- PD1-Vaxx Clinical Trial Supply Agreement with Roche
- HER-Vaxx Immunotherapy Patent Granted in Europe
- Imugene Receives $6.54 million R&D Tax Incentive
- South Korea HERVaxx Patent Grant
- Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
Later from Imugene
- Imugene HER-Vaxx Clinical Trial Collaboration with Merck
- Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
- Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
- Termination of Supply Agreement
- Clarification Announcement
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene